Dr Arno R Schleich, MD | |
348 Crossgates Blvd, Suite 1200, Brandon, MS 39042-2700 | |
(601) 824-1492 | |
(206) 350-8184 |
Full Name | Dr Arno R Schleich |
---|---|
Gender | Male |
Speciality | Plastic Surgery |
Location | 348 Crossgates Blvd, Brandon, Mississippi |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1578762027 | NPI | - | NPPES |
512I240022 | Other | MS | MEDICARE |
02251791 | Medicaid | MS |
Mailing Address | Practice Location Address |
---|---|
Dr Arno R Schleich, MD 348 Crossgates Blvd, Suite 1200, Brandon, MS 39042-2700 Ph: (601) 824-1492 | Dr Arno R Schleich, MD 348 Crossgates Blvd, Suite 1200, Brandon, MS 39042-2700 Ph: (601) 824-1492 |
News Archive
A new stimulant addiction is causing concern among emergency doctors. At Schuylkill Medical Center in Pottsville, Pa. people were arriving so agitated, violent and psychotic that a small army of medical workers was needed to hold them down. They had taken new stimulant drugs that people are calling "bath salts," and sometimes even large doses of sedatives failed to quiet them.
Modifying the risk of peripheral arterial disease (or PAD)-with healthy lifestyle changes-remains vital to one's health, note researchers in a recent issue of the Journal of Vascular and Interventional Radiology. And while PAD can progress and worsen over time, there is not enough evidence yet to advocate minimally invasive treatment in patients who have had a narrowing or blockage of a leg artery but showing no signs or symptoms of the disease, say Irish researchers in a retrospective study of more than 900 individuals.
The New York Times: A judicial ruling that "threw out parts of two gene patents and called into question thousands more" has biotechnology executives hastening "to reassure their investors that the ruling would not necessarily undermine their businesses, at least in the short run. But the executives themselves were struggling on Tuesday to figure out what the long-term impact would be."
EpiVax, Inc., a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to optimize delivery of an HIV vaccine.
› Verified 9 days ago